Quick Answer
PUMA BIOTECHNOLOGY, INC. reported Stockholders Equity of $130.34 million for fiscal year 2025.
PUMA BIOTECHNOLOGY, INC. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $130.34M | +41.5% |
| 2024 | $92.12M | +72.4% |
| 2023 | $53.44M | +147.3% |
| 2022 | $21.61M | +983.4% |
| 2021 | -$2.45M | +58.9% |
| 2020 | -$5.95M | -134.1% |
| 2019 | $17.46M | -49.1% |
| 2018 | $34.31M | -35.6% |
| 2017 | $53.30M | -74.6% |
| 2016 | $209.82M | +1.9% |
| 2015 | $206.01M | +76.0% |
| 2014 | $117.05M | +39.4% |
| 2013 | $83.99M | -34.8% |
| 2012 | $128.91M | +137.1% |
| 2011 | $54.37M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $115.27M | +62.1% | +10.1% |
| June 30, 2025 | $104.72M | +115.9% | +7.8% |
| March 31, 2025 | $97.11M | +90.5% | +5.4% |
| December 31, 2024 | $92.12M | +72.4% | +29.6% |
| September 30, 2024 | $71.09M | +83.5% | +46.5% |
| June 30, 2024 | $48.51M | +59.6% | -4.9% |
| March 31, 2024 | $50.98M | +97.2% | -4.6% |
| December 31, 2023 | $53.44M | +147.3% | +37.9% |
- PUMA BIOTECHNOLOGY, INC. showed an increase of +41.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, PUMA BIOTECHNOLOGY, INC.’s stockholders equity has grown by 139.7% (from $54.37 million to $130.34 million).
- The most recent figure is from PUMA BIOTECHNOLOGY, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: